Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
针对 CC 趋化因子配体 2 (CCL2) 的人类单克隆抗体 carlumab (CNTO 888) 治疗转移性去势抵抗性前列腺癌的 2 期研究
期刊:Investigational New Drugs
影响因子:3
doi:10.1007/s10637-012-9869-8
Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J Crabb, Susan Li, Shobha Seetharam, Thomas A Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S de Bono
